 |
|
Optimal Timing for Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes
Questions, Answers, and More Questions
Kenneth W. Mahaffey, MD;
Robert A. Harrington, MD
JAMA. 2007;297:636-639.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Contemporary management of acute coronary syndromes (ACS) has advanced in the past decade because of synergies between the tenets of basic science and findings from clinical trials.1 Clinicians, clinical investigators, and patients depend on definitive evidence to promote changes in clinical care. The current challenge is to create a clinical research system that responds to changes in the science with rapid and efficient planning of studies, acquisition of data, analysis, and dissemination of information. Such a system can provide the foundation for continued improvement in clinical care.2
Large outcome studies are needed to delineate the effects of novel therapies and treatments, as data from small trials or observational registries may be inadequate and even misleading. Human disease is complex and often incompletely understood; the interaction of pharmacologic therapies and management strategies can be unpredictable, and choices of therapies, drug dosages, and timing . . . [Full Text of this Article]
Author Affiliations: Duke Clinical Research Institute, Duke Translational Medicine Institute, Durham, NC.
RELATED ARTICLE
Routine Upstream Initiation vs Deferred Selective Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: The ACUITY Timing Trial
Gregg W. Stone, Michel E. Bertrand, Jeffrey W. Moses, E. Magnus Ohman, A. Michael Lincoff, James H. Ware, Stuart J. Pocock, Brent T. McLaurin, David A. Cox, M. Zubair Jafar, Harish Chandna, Franz Hartmann, Franz Leisch, Ruth H. Strasser, Martin Desaga, Thomas D. Stuckey, Richard B. Zelman, Ira H. Lieber, David J. Cohen, Roxana Mehran, Harvey D. White, and for the ACUITY Investigators
JAMA. 2007;297(6):591-602.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:e1-e157.
FULL TEXT
When Should GPIIb/IIIa Inhibition Be Initiated in NSTEACS?
Journal Watch Cardiology 2007;2007:3-3.
FULL TEXT
|
